Since the UK’s landmark rescheduling of cannabis-based products for medicinal use in 2018, many patients and prescribers alike have asked: is unlicensed medical cannabis still regulated in the UK? The short answer is yes — but the nuances around licensing, prescribing rules, and NHS funding often cause confusion.
In this post, we’ll break down what the 2018 rescheduling really changed, how NHS access fits with legal prescribing, the specialist-only rules for prescribers, and why unlicensed cannabis medicines remain a tricky territory. Along the way, we’ll refer to helpful resources like medicalcannabis.co.uk, a clinic directory and comparison site, and releaf.co.uk, an accessible explainer.
What Happened in 2018? The Game-Changing Rescheduling
Before November 2018, cannabis-based products were classified strictly as Schedule 1 nhs cannabis pathway guide drugs under the Misuse of Drugs Regulations (MDR) 2001. That meant legally they had "no medicinal value" and were virtually impossible to prescribe. This left many patients reliant on private prescriptions or unregulated sources.
Then, the UK government updated the MDR to reclassify cannabis-based medicinal products as Schedule 2 drugs — the same category as morphine and other strong opioids. What did this do?
- It made medical cannabis products legal for doctors to prescribe. For the first time, specialist doctors could issue prescriptions for cannabis-based medicines under a legal and regulated framework. Set the stage for NHS involvement, though the regulatory change did NOT guarantee NHS funding or routine NHS prescribing. But only if prescribed by a specialist. GPs were explicitly excluded from initiating prescriptions — only doctors on the Specialist Register (consultants) could prescribe these medicines.
To sum it up in patient language: “From late 2018, certain specialist doctors in the UK are allowed to prescribe cannabis medicines legally — but it’s not an automatic NHS treatment.”
Is Medical Cannabis Fully Regulated in the UK?
Yes—and no. Here’s why:
Licensed vs Unlicensed Cannabis Medicines
Some cannabis-based products — like Epidyolex (a purified CBD solution licensed for certain epilepsy types) — have a marketing authorisation and are considered licensed medicines. These go through standard regulatory processes by the Medicines and Healthcare products Regulatory Agency (MHRA).
However, many products used in clinical practice remain unlicensed cannabis-based medicines. These usually come as imported or compounded preparations without full UK marketing authorisation. They are often prescribed “off-label” or under special licensing rules.
Unlicensed doesn’t mean unregulated. These products are manufacturing under quality standards, but the medicines do not have the full MHRA approval that licensed drugs have.
Specialist Prescribing in the UK
Following the 2018 rescheduling, NHS England and the Department of Health clarified that only specialists registered on the General Medical Council (GMC) Specialist Register can initiate a cannabis medicine prescription. GPs can continue prescriptions started by specialists but cannot start them independently.
This specialist-only prescribing rule aims to ensure expert oversight, given the complexity and evidence gaps around medical cannabis use.
Therefore, if you want a cannabis prescription on the NHS, you typically need referral to a specialist clinic. Many private clinics can also prescribe cannabis medicines, usually at patient expense.
NHS Funding vs Legal Prescribing: What’s the Real Story?
One of the most common misunderstandings is conflating the legality of prescribing medical cannabis with it being routinely funded on the NHS. These are two separate issues.
- Legal prescribing: Since 2018, it is legal for specialists to prescribe cannabis-based medicines, licensed or unlicensed, under the correct regulations. NHS funding: NHS England has not established routine funding pathways for most medical cannabis products. Prescribers must apply for individual funding requests (IFRs), which often face rejections due to limited robust clinical evidence.
This means most patients seeking cannabis treatments pay privately unless they qualify for exceptional NHS funding. This gap between legal prescribing and NHS support causes frustration and confusion.
For a clearer patient-friendly explanation, releaf.co.uk offers simple language guides about NHS prescribing and funding realities.
Why Are Unlicensed Cannabis-Based Medicines Viewed With Caution by the NHS?
The NHS and NICE (National Institute for Health and Care Excellence) approach unlicensed cannabis medicines cautiously for several reasons:
Limited high-quality clinical trial data: While anecdotal and observational evidence exists, NICE finds a lack of sufficiently robust data demonstrating clear benefits across many conditions. Variable product composition: Unlicensed cannabis medicines can vary in cannabinoid concentrations and purity, complicating consistent dosing and safety monitoring. Cost considerations: These medicines can be expensive, and without clear evidence, NHS budgets prioritise other treatments with established effectiveness.Hence, many specialists are cautious prescribing unlicensed cannabis medicines on the NHS, reflecting the balance of risks, evidence, and funding.
Putting It All Together: What Does This Mean for Patients?
Here’s a summary in simple terms:
- Medical cannabis can be legally prescribed in the UK — but only by specialist doctors on the GMC Specialist Register. Most cannabis-based medicines remain unlicensed but use regulated manufacturing; they haven’t passed the full MHRA approval. The NHS does not routinely fund medical cannabis treatments, so private prescriptions are common, with clinics listed on medicalcannabis.co.uk. Specialists and the NHS remain cautious about unlicensed cannabis medicines due to evidence gaps and cost-related concerns.
If you’re considering medical cannabis, expect to undergo specialist assessment. It’s important to know that legal prescribing doesn’t guarantee NHS coverage or availability.
Price Transparency: What Does Medical Cannabis Cost?
One challenge for patients is the lack of standardised pricing for cannabis medicines. No specific prices have been officially stated in public NHS documents or consistent government sources.
Private clinics listed on medicalcannabis.co.uk may offer price information, but these vary based on product type, dosage, and clinic fees.
The key takeaway: if you see pricing figures quoted elsewhere, ask where exactly those numbers come from, and remember that prices might change depending https://smoothdecorator.com/how-can-i-spot-overconfident-medical-cannabis-marketing-in-the-uk/ on your prescription details.
Additional Resources and Next Steps
For those seeking more guidance about medical cannabis in the UK, these websites are excellent starting points:
- MedicalCannabis.co.uk — A comprehensive directory of clinics, private providers, and product comparisons. Releaf.co.uk — Easy-to-understand guides about medical cannabis, NHS prescribing, and patient FAQs.
Final Thoughts
The 2018 rescheduling opened the door for regulated medical cannabis prescribing in the UK — but it came with clear guardrails. Only specialists can prescribe, the NHS still largely does not fund these medicines, and unlicensed products remain cautiously handled due to evidence limitations.
Regulation is certainly in place, but patients must navigate a complex system where legal prescribing and NHS funding don’t always align. By understanding these distinctions, patients and carers can better advocate for informed treatment options and realistic expectations.
If you’re considering medical cannabis, starting with a referral to a specialist clinic (private or NHS) listed on medicalcannabis.co.uk is a practical first step.